CliffBio
small molecule

DOCETAXEL

DOCETAXEL

Loss of exclusivity—loss of exclusivity
CompanyAlembic →See this company's full patent-cliff portfolio

Drug detail

Brand nameDOCETAXEL
Active ingredientDOCETAXEL
Strength80MG/8ML (10MG/ML)
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalFebruary 2023
Marketing statusRX

More from Alembic

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.